Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

Janssen’s teclistamab granted conditional marketing authorisation by EC

The decision makes teclistamab the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma

- PMLiVE

Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria

ABP 959 demonstrated no ‘clinically meaningful’ difference to the reference product in the phase 3 study

- PMLiVE

Alpha Cognition announces positive results for Alzheimer’s disease treatment

The number of people with dementia is predicted to increase to around one million by 2025, increasing to 1.6 million by 2040

- PMLiVE

Parkinson’s UK and Parkinson’s Foundation partner to accelerate drug development

Parkinson's disease is the fastest growing neurological condition worldwide, currently affecting 145,000 people in the UK

- PMLiVE

AI: powering healthcare, empowering patients Physician perceptions of AI and the future of pharma

In the face of the coronavirus, innovative technologies such as artificial intelligence (AI) and machine learning (ML) have proven vital for the protection and promotion of public health.According to a...

- PMLiVE

Moderna seeks FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The application is based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Pfizer and BioNTech release COVID-19 vaccine trial results for children under five

The phase 2/3 trial results showed that the vaccine was 73.2% effective in protecting children aged six months to four years

- PMLiVE

Roche launches digital PCR system to identify ultra-rare and emerging disease mutations

The diagnostics platform will allow researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions

- PMLiVE

Merck granted fast track designation by FDA for end-stage renal disease therapy

MK-2060 is currently being investigated in a phase 2 study to evaluate the efficacy and safety of two different doses

- PMLiVE

100,000 doses of Janssen’s COVID-19 delivered to Ukraine under COVAX initiative

WHO in Ukraine has trained more than 100 medical workers across the country to conduct further training on the use of Ad26.COV2-S

- PMLiVE

ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS

With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...

Wilmington Healthcare

- PMLiVE

Cannes Lions shows health creative is becoming an art form

If you ever want an example of art imitating life, look no further than Cannes Lions 2022. Because just like life these past two years – in fact possibly because...

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links